A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants (NCT07175285)

🧪 Interventions in This Study

• Current standard of care treatment options (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (65 Sites)

Showing the first 25 of 65 sites.

• Arizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa — Mesa, Arizona
• Local Institution - 0054 — La Jolla, California
• Local Institution - 0001 — La Palma, California
• Local Institution - 0071 — Los Angeles, California
• Rheumatology Center of San Diego — San Diego, California
• Centre for Rheumatology, Immunology and Arthritis — Fort Lauderdale, Florida
• South Florida Rheumatology — Hollywood, Florida
• LIFE Clinical Trials — Margate, Florida
• One- Rheumatology — Palm Beach Gardens, Florida
• Local Institution - 0069 — Atlanta, Georgia
• Willow Rheumatology & Wellness — Willowbrook, Illinois
• Arthritis & Rheumatism Associates — Rockville, Maryland
• Local Institution - 0034 — Ann Arbor, Michigan
• AA MRC — Grand Blanc, Michigan
• Local Institution - 0070 — Kalispell, Montana
• Sahni Rheumatology & Therapy — West Long Branch, New Jersey
• Kings County Hospital Center - Brooklyn — Brooklyn, New York
• DJL Clinical Research, PLLC — Charlotte, North Carolina
• Local Institution - 0037 — Durham, North Carolina
• Oklahoma Medical Research Foundation — Oklahoma City, Oklahoma
• Local Institution - 0052 — Philadelphia, Pennsylvania
• Murfreesboro Medical Clinic — Murfreesboro, Tennessee
• Arthritis Care of Texas - Corpus Christi — Corpus Christi, Texas
• El Paso Medical Research Institute (MedResearch, Inc) — El Paso, Texas
• Local Institution - 0051 — Van Vleck, Texas

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Systemic Lupus Erythematosus (SLE)

• Descartes-08 for Patients With Systemic Lupus Erythematosus — Oceanside, California
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Los Angeles, California
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Farmington, Connecticut
• Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — Bethesda, Maryland
• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires — Bethesda, Maryland

Explore by condition: All Systemic Lupus Erythematosus (SLE) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.